Robert W. Baird initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $32.00

4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

3 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

3 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Troy Ignelzi as an independent member of its Board of Directors and as Chair of the Audit Committee. Mr. Ignelzi brings nearly two decades of financial leadership and industry experience to Contineum's board. "I am extremely pleased to welcome Troy to the Contineum board. Troy's recent public markets experience, coupled with his proven t

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced participation in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference, September 4-6, 2024, NY, NY: Carmine Stengone, Contineum's President and CEO, will present on Wednesday, September 4, 2024, at 7:00 am ET. H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, NY, NY:

- Strengthened Board and management with appointments of experienced biotech leaders Troy Ignelzi, Sarah Boyce, John Healy and Kristina Haeckl - - Strong cash position of $219 million at the end of Q2 will support multiple clinical readouts - Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "Our tea

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced encouraging preclinical data on PIPE-307, a potentially first-in-class M1 receptor antagonist in development for patients with relapse-remitting multiple sclerosis (RRMS), were published online in the peer-reviewed journal, Proceedings of the National Academy of Science (PNAS). The published data provide early evidence that PIPE-307 is a potentially first-

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that Company management will participate in the 45th Annual Goldman Sachs Healthcare Conference, taking place June 10-13, 2024 in Miami. Carmine Stengone, President and Chief Executive Officer of Contineum, will participate in a fireside chat on Monday, June 10, 2024 at 8:40 am Eastern Time, and management will host one-on-one meetings with investors. A

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of John Healy as General Counsel & Corporate Secretary. "We are excited that John has joined Contineum, as he brings more than twenty years of law firm and in house legal experience in the life sciences industry to Contineum," said Carmine Stengone, Chief Executive Officer of Contineum. "John will be a tremendous asset as a member of our le

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Troy Ignelzi as an independent member of its Board of Directors and as Chair of the Audit Committee. Mr. Ignelzi brings nearly two decades of financial leadership and industry experience to Contineum's board. "I am extremely pleased to welcome Troy to the Contineum board. Troy's recent public markets experience, coupled with his proven t

-Contineum is focused on leading the Neuroscience, Inflammation and Immunology (NI&I) field- -Successful completion of Initial Public Offering with strong syndicate of existing and new investors- Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of NI&I indications, today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. "2024 has been a pivotal year of growth for Contineum, as we transitioned to a publicly traded com